Jonathan Gardner's profile photo

Jonathan Gardner

Charlottesville

Senior Reporter at BioPharma Dive

Senior reporter, BioPharma Dive. Father of 1, husband of 1, son of 2, brother of 2, uncle of 7. Opinions are mine. RTs are not endorsements. Darn good runner.

Featured in: Favicon biopharmadive.com Favicon healthcaredive.com Favicon newsbreak.com Favicon supplychaindive.com Favicon k12dive.com Favicon evaluate.com Favicon medtechdive.com Favicon cfodive.com Favicon greenbeltnewsreview.com Favicon legaldive.com

Articles

  • Obesity drug data helps Rhythm defy market slide

    2 weeks ago | biopharmadive.com | Jonathan Gardner

    Dive Brief:Rhythm Pharmaceuticals on Monday said its drug for rare obesity conditions met the main goal of a Phase 3 clinical trial, helping people with weight gain triggered by brain injury lose about one-sixth of their body weight over one year of treatment. The company plans to ask U.S. and European regulators to expand approval of the drug, called setmelanotide.

  • Makary confirmed by Senate as FDA commissioner

    4 weeks ago | biopharmadive.com | Jonathan Gardner

    The U.S. Senate on Tuesday confirmed Johns Hopkins University surgeon Martin Makary to be commissioner of the Food and Drug Administration, giving him authority over an agency that regulates a wide swathe of the U.S. economy that includes food, tobacco, drugs and medical devices. Three Democrats joined 53 Republicans to confirm Makary in a 56-44 vote. Sen. Bernie Sanders, the senior minority member of the Senate Health, Education, Labor and Pensions Committee, voted no.

  • Merck bets $200M on a new type of heart pill

    1 month ago | biopharmadive.com | Jonathan Gardner

    Dive Brief:Merck & Co. has entered a competitive race for a new type of heart drug, announcing Tuesday it will pay China-based Jiangsu Hengrui Pharmaceuticals $200 million upfront to license a pill that blocks a protein particle believed to contribute to blood vessel blockages. Per deal terms, Merck will receive rights outside of the greater China region to the therapy, dubbed HRS-5346 and is currently in Phase 2 testing.

  • Novo adds to obesity drug pipeline via $200M deal with China-based biotech

    1 month ago | biopharmadive.com | Jonathan Gardner

    Dive Brief:Novo Nordisk is expanding its pipeline of obesity medicines, announcing Monday it will pay China-based United Laboratories International Holdings $200 million upfront to license an experimental “triple agonist” weight loss shot that could take on Eli Lilly’s retatrutide.

  • J&J boosts US manufacturing as big pharma reshores

    1 month ago | biopharmadive.com | Jonathan Gardner

    Dive Brief:Johnson & Johnson is planning a major U.S. expansion, announcing Friday it will spend $55 billion over the next four years on manufacturing, research and development and technology in its domestic market. The investments will support three advanced manufacturing facilities and expansion of other sites in its pharmaceutical and medical technology businesses, J&J said.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
3K
Tweets
9K
DMs Open
No
Jon Gardner
Jon Gardner @ByJonGardner
30 Oct 23

Coming out of hibernation (see me at BlueSky!) to look at the $SRPT stream and remind everybody ....

Jon Gardner
Jon Gardner @ByJonGardner

1/ "It's always good news for $SRPT!" is a phrase I began tweeting back in the days when $SRPT was in a neck-and-neck race with $BMRN to get the first exon-skipping agent on the market.

Jon Gardner
Jon Gardner @ByJonGardner
21 Nov 22

I love these M&A drawings. $TEVA https://t.co/ppVQSrBtRq

Jon Gardner
Jon Gardner @ByJonGardner
11 Nov 22

It would be an interesting end to the PARP story if it turned out that, like iniparib, none of the PARPs actually inhibited PARP. $AZN $GSK $CLVS $MRK